Gregory has made over 1 trades of the Y-Mabs Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Gregory sold 5,882 units of YMAB stock worth $157,049 on 29 August 2019.
The largest trade Gregory's ever made was selling 5,882 units of Y-Mabs Therapeutics Inc stock on 29 August 2019 worth over $157,049. On average, Gregory trades about 2,941 units every 0 days since 2019.
You can see the complete history of Gregory Raskin stock trades at the bottom of the page.
Gregory's mailing address filed with the SEC is C/O MEMORIAL SLOAN KETTERING CANCER, CENTER, 1275 YORK AVENUE, BOX 524, NEW YORK, NY, 10065.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad és Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: